ERBB2 and triple-negative breast carcinoma: The antibody drug conjugate sacituzumab govitecan has been shown to improve progression free survival and overall survival in patients with triple negative breast cancer (TNBC) and HR+/HER2- MBC when compared to single agent chemotherapy, with evidence of CNS penetration [18–21].